The bystander effect of the Nitroreductase/CB 1954 Enzyme/Prodrug system is due to a cell-permeable metabolite

Human Gene Therapy

Volumn 8, Issue 6, 1997, Pages 709-717

  Bridgewater, J A ^a   Knox, R J ^a   Pitts, J D ^b   Collins, M K ^a   Springer, C J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; NITROREDUCTASE; PRODRUG;

ANIMAL CELL; ARTICLE; BYSTANDER EFFECT; CANCER CELL DESTRUCTION; CELL JUNCTION; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG METABOLISM; GENE TARGETING; GENETIC TRANSDUCTION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TARGET CELL DESTRUCTION; TUMOR CELL;

EID: 0030956976     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1997.8.6-709     Document Type: Article

References (31)

1. BARBA, D., HARDIN, J., SADELAIN, M., and GAGE, F.H. (1994). Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Natl. Acad. Sci. USA 91, 4348-4352.
2. BRIDGEWATER, J.A., SPRINGER, C.J., KNOX, R.J., MINTON, N.P., MICHAEL, N.P., and COLLINS, M.K. (1995). Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur. J. Cancer 31A, 2362-2370.
3. CARUSO, M., PANIS, Y., GAGANDEEP, S., HOUSSIN, D., SALZMANN, J.L., and KLATZMANN, D. (1993). Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl. Acad. Sci. USA 90, 7024-7028.
4. CHEN, L., and WAXMAN, D.J. (1995). Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: Development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res. 55, 581-589.
5. CULVER, K.W., RAM, Z., WALLBRIDGE, S., ISHTI, H., OLDFIELD, E.H., and BLAESE, R.M. (1992). In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors [see comments]. Science 256, 1550-1552.
6. EVAN, G.I., LEWIS, G.K., RAMSAY, G., and BISHOP, J.M. (1985). Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol. Cell. Biol. 5, 3610-3616.
7. FICK, J., BARKER, F.N., DAZIN, P., WESTPHALE, E.M., BEYER, E.C., and ISRAEL, M.A. (1995). The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc. Natl. Acad. Sci. USA 92, 11071-11075.
8. FINBOW, M.E., JOHN, S., KAM, E., APPS, D.K., and PITTS, J.D. (1993). Disposition and orientation of ductin (DCCD-reactive vacuolar H(+)-ATPase subunit) in mammalian membrane complexes. Exp. Cell Res. 207, 261-270.
9. FREEMAN, S.M., ABBOUD, C.N., WHARTENBY, K.A., PACKMAN, C.H., KOEPLIN, D.S., MOOLTEN, F.L., and ABRAHAM, G.N. (1993). The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53, 5274-5283.
10. FREEMAN, S.M., RAMESH, R., SHASTRI, M., MUNSHI, A., JENSEN, A.K., and MARROGI, A.J. (1995). The role of cytokines in mediating the bystander effect using HSV-tk xenogeneic cells. Cancer Lett. 92, 167-174.
11. FRIEDLOS, F., QUINN, J., KNOX, R.J., and ROBERTS, J.J. (1992). The properties of total adducts and interstrand crosslinks in the DNA of cells treated with CB1954. Biochem. Pharmacol. 43, 1249-1254.
12. HUBER, B.E., AUSTIN, E.A., GOOD, S.S., KNICK, V.C., TIBBELS, S., and RICHARDS, C.A. (1993). In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res. 53, 4619-4626.
13. HUGHES, B.W., WELLS, A.H., BEBOK, Z., GADI, V.K., GARVER, R.J., PARKER, W.B., and SORSCHER, E.J. (1995). Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res. 55, 3339-3345.
14. IDO, A., NAKATA, K., KATO, Y., NAKAO, K., MURATA, K., FUJITA, M., ISHII, N., TAMAOKI, T., SHIKU, H., and NAGATAKI, S. (1995). Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. Cancer Res. 55, 3105-3109.
15. KNOX, R.J., FRIEDLOS, F., MARCHBANK, T., and ROBERTS, J.J. (1991). Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species. Biochem. Pharmacol. 42, 1691-1697.
16. LAEMMLI, U.K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.
17. MANOME, Y., ABE, M., HAGEN, M.F., FINE, H.A., and KUFE, D.W. (1994). Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir. Cancer Res. 54, 5408-5413.
18. MESNIL, M., PICCOLI, C., TIRABY, G., WILLECKE, K., and YAMASAKI, H. (1996). Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc. Natl. Acad. Sci. USA 91, 1831-1835.
19. MULLEN, C., COALE, M.M., LOWE, R., and BLAESE, R.M. (1996). Tumours expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumour. Cancer Res. 54, 1503-1506.
20. NABEL, G.J., CHANG, A.E., NABEL, E.G., PLAUTZ, G.E., ENSMINGER, W., FOX, B.A., FELGNER, P., SHU, S., and CHO, K. (1994). Immunotherapy for cancer by direct gene transfer into tumors. Hum. Gene Ther. 5, 57-77.
21. O'MALLEY, B.J., CHEN, S.H., SCHWARTZ, M.R., and WOO, S.L. (1995). Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res. 55, 1080-1085.
22. OLDFIELD, E.H., RAM, Z., CULVER, K.W., BLAESE, R.M., DEVROOM, H.L., and ANDERSON, W.F. (1993). Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum. Gene Ther. 4, 39-69.
23. OLDFIELD, E.H., RAM, Z., CHIANG, Y., and BLAESE, R.M. (1995). Intrathecal gene therapy for the treatment of leptomeningeal carcinomatosis. GTI 0108. A phase I/II study. Hum. Gene Ther. 6, 55-85.
24. RAM, Z., CULVER, K.W., WALBRIDGE, S., BLAESE, R.M., and OLDFIELD, E.H. (1993). In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 53, 83-88.
25. RAM, Z., WALBRIDGE, S., OSHIRO, E.M., VIOLA, J.J., CHIANG, Y., MUELLER, S.N., BLAESE, R.M., and OLDFIELD, E.H. (1994). Intrathecal gene therapy for malignant leptomeningeal neoplasia. Cancer Res. 54, 2141-2145.
26. RICHARDS, C.A., AUSTIN, E.A., and HUBER, B.E. (1995). Transcriptional regulatory sequences of carcinoembryonic antigen: Identification and use with cytosine deaminase for tumor-specific gene therapy. Hum. Gene Ther. 6, 881-893.
27. SKEHAN, P., STORENG, R., SCUDIERO, D., MONKS, A., MCMAHON, J., VISTICA, D., WARREN, J.T., BOKESCH, H., KENNEY, S., and BOYD, M.R. (1990). New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82, 1107-1112.
28. SMYTHE, W.R., HWANG, H.C., AMIN, K.M., ECK, S.L., DAVIDSON, B.L., WILSON, J.M., KAISER, L.R., and ALBELDA, S.M. (1994). Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res. 54, 2055-2059.
29. TOCHER, J.H., and EDWARDS, D.I. (1995). The interaction of nitroaromatic drugs with aminothiols. Biochem. Pharmacol. 50, 1367-1371.
30. VILE, R.G., and HART, I.R. (1993). Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res. 53, 3860-3864.
31. VILE, R.G., NELSON, J.A., CASTLEDEN, S., CHONG, H., and HART, I.R. (1994). Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 54, 6228-6234.